FY2028 EPS Estimates for TSE:ONC Raised by HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Analysts at HC Wainwright upped their FY2028 earnings estimates for shares of Oncolytics Biotech in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.60 per share for the year, up from their previous estimate of $0.58. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday.

Oncolytics Biotech Stock Performance

Shares of ONC stock opened at C$1.38 on Friday. Oncolytics Biotech has a 12-month low of C$1.15 and a 12-month high of C$2.32. The firm has a market capitalization of C$106.07 million, a price-to-earnings ratio of -3.63 and a beta of 1.35. The business has a 50 day simple moving average of C$1.50 and a 200 day simple moving average of C$1.45. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.